256 related articles for article (PubMed ID: 16571822)
1. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle.
Yap MW; Dodding MP; Stoye JP
J Virol; 2006 Apr; 80(8):4061-7. PubMed ID: 16571822
[TBL] [Abstract][Full Text] [Related]
2. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.
Keckesova Z; Ylinen LM; Towers GJ
J Virol; 2006 May; 80(10):4683-90. PubMed ID: 16641261
[TBL] [Abstract][Full Text] [Related]
3. Evolution of a TRIM5-CypA splice isoform in old world monkeys.
Newman RM; Hall L; Kirmaier A; Pozzi LA; Pery E; Farzan M; O'Neil SP; Johnson W
PLoS Pathog; 2008 Feb; 4(2):e1000003. PubMed ID: 18389077
[TBL] [Abstract][Full Text] [Related]
4. Cyclophilin A protects HIV-1 from restriction by human TRIM5α.
Kim K; Dauphin A; Komurlu S; McCauley SM; Yurkovetskiy L; Carbone C; Diehl WE; Strambio-De-Castillia C; Campbell EM; Luban J
Nat Microbiol; 2019 Dec; 4(12):2044-2051. PubMed ID: 31636416
[TBL] [Abstract][Full Text] [Related]
5. Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses.
Schaller T; Ylinen LM; Webb BL; Singh S; Towers GJ
J Virol; 2007 Sep; 81(18):10055-63. PubMed ID: 17609268
[TBL] [Abstract][Full Text] [Related]
6. The control of viral infection by tripartite motif proteins and cyclophilin A.
Towers GJ
Retrovirology; 2007 Jun; 4():40. PubMed ID: 17565686
[TBL] [Abstract][Full Text] [Related]
7. Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core.
Selyutina A; Persaud M; Simons LM; Bulnes-Ramos A; Buffone C; Martinez-Lopez A; Scoca V; Di Nunzio F; Hiatt J; Marson A; Krogan NJ; Hultquist JF; Diaz-Griffero F
Cell Rep; 2020 Mar; 30(11):3766-3777.e6. PubMed ID: 32187548
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of microtubules and dynein rescues human immunodeficiency virus type 1 from owl monkey TRIMCyp-mediated restriction in a cellular context-specific fashion.
Pawlica P; Dufour C; Berthoux L
J Gen Virol; 2015 Apr; 96(Pt 4):874-886. PubMed ID: 25502651
[TBL] [Abstract][Full Text] [Related]
9. The ability of multimerized cyclophilin A to restrict retrovirus infection.
Javanbakht H; Diaz-Griffero F; Yuan W; Yeung DF; Li X; Song B; Sodroski J
Virology; 2007 Oct; 367(1):19-29. PubMed ID: 17574642
[TBL] [Abstract][Full Text] [Related]
10. The design of artificial retroviral restriction factors.
Yap MW; Mortuza GB; Taylor IA; Stoye JP
Virology; 2007 Sep; 365(2):302-14. PubMed ID: 17493656
[TBL] [Abstract][Full Text] [Related]
11. Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type.
Matsuoka S; Dam E; Lecossier D; Clavel F; Hance AJ
Retrovirology; 2009 Mar; 6():21. PubMed ID: 19254360
[TBL] [Abstract][Full Text] [Related]
12. Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains.
Li X; Li Y; Stremlau M; Yuan W; Song B; Perron M; Sodroski J
J Virol; 2006 Jul; 80(13):6198-206. PubMed ID: 16775307
[TBL] [Abstract][Full Text] [Related]
13. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
Stremlau M; Perron M; Welikala S; Sodroski J
J Virol; 2005 Mar; 79(5):3139-45. PubMed ID: 15709033
[TBL] [Abstract][Full Text] [Related]
14. Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1.
Lin TY; Emerman M
Virology; 2008 Sep; 379(2):335-41. PubMed ID: 18678385
[TBL] [Abstract][Full Text] [Related]
15. Independent evolution of an antiviral TRIMCyp in rhesus macaques.
Wilson SJ; Webb BL; Ylinen LM; Verschoor E; Heeney JL; Towers GJ
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3557-62. PubMed ID: 18287035
[TBL] [Abstract][Full Text] [Related]
16. The V86M mutation in HIV-1 capsid confers resistance to TRIM5α by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import.
Veillette M; Bichel K; Pawlica P; Freund SM; Plourde MB; Pham QT; Reyes-Moreno C; James LC; Berthoux L
Retrovirology; 2013 Feb; 10():25. PubMed ID: 23448277
[TBL] [Abstract][Full Text] [Related]
17. General Model for Retroviral Capsid Pattern Recognition by TRIM5 Proteins.
Wagner JM; Christensen DE; Bhattacharya A; Dawidziak DM; Roganowicz MD; Wan Y; Pumroy RA; Demeler B; Ivanov DN; Ganser-Pornillos BK; Sundquist WI; Pornillos O
J Virol; 2018 Feb; 92(4):. PubMed ID: 29187540
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor.
Chan E; Schaller T; Eddaoudi A; Zhan H; Tan CP; Jacobsen M; Thrasher AJ; Towers GJ; Qasim W
Hum Gene Ther; 2012 Nov; 23(11):1176-85. PubMed ID: 22909012
[TBL] [Abstract][Full Text] [Related]
19. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1.
Diaz-Griffero F; Vandegraaff N; Li Y; McGee-Estrada K; Stremlau M; Welikala S; Si Z; Engelman A; Sodroski J
Virology; 2006 Aug; 351(2):404-19. PubMed ID: 16650449
[TBL] [Abstract][Full Text] [Related]
20. The Three-Fold Axis of the HIV-1 Capsid Lattice Is the Species-Specific Binding Interface for TRIM5α.
Morger D; Zosel F; Bühlmann M; Züger S; Mittelviefhaus M; Schuler B; Luban J; Grütter MG
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
